Varela M C, Arce A, Greiner B, Schwald M, Aicher L, Wahl D, Grenet O, Steiner S
Preclinical Safety, Toxicology, Novartis Pharma AG, Basel, Switzerland.
Biochem Pharmacol. 1998 Jun 15;55(12):2043-6. doi: 10.1016/s0006-2952(98)00025-2.
Recently, we reported that in rat, cyclosporine A (CsA) markedly decreases the levels of calbindin-D (CABP-D) 28 kDa in kidney. CABP-D 28 kDa is a calcium-binding protein which is highly expressed in calcium-transporting tissues such as kidney or brain. In this study, we investigated whether, in addition to the kidney, CsA also has an effect on CABP-D 28 kDa in rat brain. Three groups of male Wistar rats received 15 mg/kg/day or 50 mg/kg/day of CsA orally for 12 days, whereas controls received vehicle solution for the same period. CABP-D 28-kDa protein and CsA were quantified in homogenates of kidney, cerebral cortex and cerebellum, and the localization of CABP-D 28 kDa was assessed in the different tissue sections by immunohistochemistry. In kidney, CABP-D 28 kDa was strongly and dose dependently decreased, and was located in tubular epithelial cells. In brain, CABP-D 28 kDa was not changed and was mainly located in pyramidal cells of the cortex and in cerebellum exclusively in Purkinje cells. High CsA concentrations were measured in kidney, more than 17-fold greater than those found in cortex. In cerebellum, CsA was below the limit of detection. These data suggest that at clinically relevant doses, CsA may not affect CABP-D 28-kDa levels in brain.
最近,我们报道在大鼠中,环孢素A(CsA)显著降低了肾脏中28 kDa钙结合蛋白-D(CABP-D)的水平。28 kDa的CABP-D是一种钙结合蛋白,在肾脏或大脑等钙转运组织中高度表达。在本研究中,我们调查了除肾脏外,CsA是否也对大鼠大脑中的28 kDa CABP-D有影响。三组雄性Wistar大鼠口服15 mg/kg/天或50 mg/kg/天的CsA,持续12天,而对照组在同一时期接受赋形剂溶液。对肾脏、大脑皮层和小脑的匀浆中的28 kDa CABP-D蛋白和CsA进行定量,并通过免疫组织化学在不同组织切片中评估28 kDa CABP-D的定位。在肾脏中,28 kDa的CABP-D强烈且呈剂量依赖性降低,且位于肾小管上皮细胞中。在大脑中,28 kDa的CABP-D没有变化,主要位于皮层的锥体细胞中,在小脑中仅位于浦肯野细胞中。在肾脏中检测到高浓度的CsA,比在皮层中发现的浓度高17倍以上。在小脑中,CsA低于检测限。这些数据表明,在临床相关剂量下,CsA可能不会影响大脑中28 kDa CABP-D的水平。